Literature DB >> 7507369

Epitope-dependent nonreciprocal regulation of IgE and IgG2a antibody formation.

L Kolbe1, C Heusser, E Kölsch.   

Abstract

The antigen dose-dependent production of IgE versus IgG2a antibodies has been investigated using keyhole limpet hemocyanin (KLH) and bee venom phospholipase A2 (PLA2) as antigens. Repeated injections of minute doses (0.1 microgram/mouse) of KLH into CBA/J mice lead to relatively high titers of IgE antibodies which are gradually reduced in animals that had received higher doses of antigen. In contrast, the IgG2a antibody titers are inversely correlated, resulting in low titers after repeated injection of 0.1 microgram KLH and high titers after repeated doses of 10 micrograms/mouse. With PLA2 as antigen, one finds a comparable dose-dependent downregulation of IgE antibody production. In contrast to the response to KLH, there is, however, only a marginal IgG2a response at all doses tested, and no dose-dependent increase can be found. The data show that an inverse regulation of IgE and IgG2a responses is not mandatory. Instead there seems to be an additional regulation dictated by antigen epitopes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7507369     DOI: 10.1159/000236630

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  4 in total

1.  Are we getting enough allergens?

Authors:  Allan Linneberg
Journal:  Int Arch Allergy Immunol       Date:  2008-06-03       Impact factor: 2.749

2.  Antigen dose-dependent predominance of either direct or sequential switch in IgE antibody responses.

Authors:  S Sudowe; A Rademaekers; E Kölsch
Journal:  Immunology       Date:  1997-07       Impact factor: 7.397

Review 3.  Cell and molecular biology of chemical allergy.

Authors:  I Kimber; R J Dearman
Journal:  Clin Rev Allergy Immunol       Date:  1997       Impact factor: 8.667

4.  Effect of different sensitizing doses of antigen in a murine model of atopic asthma.

Authors:  K Sakai; A Yokoyama; N Kohno; K Hiwada
Journal:  Clin Exp Immunol       Date:  1999-10       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.